PIPE-791 enters clinical phase: Pipeline Therapeutics’ precision approach to neuroinflammation treatment
Pipeline Therapeutics, a clinical-stage biopharmaceutical firm specializing in precision neuroregeneration, has announced the initiation of dosing for the Phase 1 clinical trial of PIPE-791 in healthy volunteers. The novel small molecule antagonist targets the lysophosphatidic acid 1 receptor (LPA1), setting the stage for a new era in treating CNS indications. Carmine Stengone, President and CEO […]